104113-52-2

Usage

Uses

Used in Pharmaceutical Applications:
(5S,6S,9S,10R,15R)-19,20-dioxo-5,6,7,8,9,10,11,14-octahydro-5,10:9,15-dicycloretinol is used as a pharmaceutical compound for its potential therapeutic effects. Its unique molecular structure and oxygenated nature may contribute to its efficacy in treating various medical conditions, although further research is needed to fully understand its applications and mechanisms of action.
Used in Medical Research:
In the field of medical research, (5S,6S,9S,10R,15R)-19,20-dioxo-5,6,7,8,9,10,11,14-octahydro-5,10:9,15-dicycloretinol can be used as a research tool to study the effects of cycloretinoid derivatives on biological systems. Its complex structure and potential biological properties make it an interesting subject for exploring new therapeutic approaches and understanding the underlying mechanisms of action.

Upstream product

• 564-20-5 (3aR)-(+)-sclareolide 
• 3243-36-5 (1S,4aS,8aS)-1,2,3,4,4a,5,6,7,8,8a-decahydro-5,5,8a-trimethyl-2-methylene-1-naphthaleneacetaldehyde 
• 434284-14-7 N-methoxy-N-methyl-2-((1S,4aS,8aS)-5,5,8a-trimethyl-2-methylenedecahydronaphthalen-1-yl)acetamide 
• 190264-38-1 2-((1R,2R,4aS,8aS)-2-hydroxy-2,5,5,8a-tetramethyldecahydronaphthalen-1-yl)-N-methoxy-N-methylacetamide 

Relevant academic research and scientific papers

Total Synthesis of the Labdane Diterpenes Galanal A and B from Geraniol

The first total synthesis of galanal A and B has been achieved from naturally occurring geraniol. Key steps in this synthesis are the use of a Lewis acid assisted chiral Br?nsted acid (chiral LBA) mediated cationic polyene cyclization and a titanocene-mediated radical cyclization for the asymmetric assembly of the "AB" ring and the construction of the all-carbon quaternary center at the junction of the "BC" ring, respectively.

Synthesis of labdane diterpenes galanal A and B from (+)-sclareolide

The first chemical synthesis of galanal A and B was achieved by a concise and highly efficient pathway starting from commercially available (+)-sclareolide and features a Wittig reaction and a titanocene-mediated radical cyclization as the key steps.

GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR MODULATORS AND USES THEREOF IN REGULATING BLOOD GLUCOSE LEVELS

The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.